The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Spinal Muscular Atrophy Treatment Market Research Report 2025
Synopsis
Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot respond to signals from the nerves, they atrophy — weaken and shrink — from inactivity.
The global Spinal Muscular Atrophy Treatment market was valued at US$ 1249.5 million in 2023 and is anticipated to reach US$ 1952.4 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
North American market for Spinal Muscular Atrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Spinal Muscular Atrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Spinal Muscular Atrophy Treatment in Early Stage Candidates is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Spinal Muscular Atrophy Treatment include Novartis AG, Pfizer, Biogen, Roche, Cytokinetics, Ionis Pharmaceuticals, NMD Phrama, Beijing Jinlan Gene Technology and Hanugen Theraputics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy Treatment.
Report Scope
The Spinal Muscular Atrophy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal Muscular Atrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis AG
Pfizer
Biogen
Roche
Cytokinetics
Ionis Pharmaceuticals
NMD Phrama
Beijing Jinlan Gene Technology
Hanugen Theraputics
Scholar Rock Holding
Segment by Type
Oral
Parenteral
Segment by Application
Early Stage Candidates
Late Stage Candidates
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot respond to signals from the nerves, they atrophy — weaken and shrink — from inactivity.
The global Spinal Muscular Atrophy Treatment market was valued at US$ 1249.5 million in 2023 and is anticipated to reach US$ 1952.4 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
North American market for Spinal Muscular Atrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Spinal Muscular Atrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Spinal Muscular Atrophy Treatment in Early Stage Candidates is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Spinal Muscular Atrophy Treatment include Novartis AG, Pfizer, Biogen, Roche, Cytokinetics, Ionis Pharmaceuticals, NMD Phrama, Beijing Jinlan Gene Technology and Hanugen Theraputics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy Treatment.
Report Scope
The Spinal Muscular Atrophy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal Muscular Atrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis AG
Pfizer
Biogen
Roche
Cytokinetics
Ionis Pharmaceuticals
NMD Phrama
Beijing Jinlan Gene Technology
Hanugen Theraputics
Scholar Rock Holding
Segment by Type
Oral
Parenteral
Segment by Application
Early Stage Candidates
Late Stage Candidates
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Spinal Muscular Atrophy Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Parenteral
1.3 Market by Application
1.3.1 Global Spinal Muscular Atrophy Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Early Stage Candidates
1.3.3 Late Stage Candidates
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Spinal Muscular Atrophy Treatment Market Perspective (2019-2030)
2.2 Spinal Muscular Atrophy Treatment Growth Trends by Region
2.2.1 Global Spinal Muscular Atrophy Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Spinal Muscular Atrophy Treatment Historic Market Size by Region (2019-2024)
2.2.3 Spinal Muscular Atrophy Treatment Forecasted Market Size by Region (2025-2030)
2.3 Spinal Muscular Atrophy Treatment Market Dynamics
2.3.1 Spinal Muscular Atrophy Treatment Industry Trends
2.3.2 Spinal Muscular Atrophy Treatment Market Drivers
2.3.3 Spinal Muscular Atrophy Treatment Market Challenges
2.3.4 Spinal Muscular Atrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Spinal Muscular Atrophy Treatment Players by Revenue
3.1.1 Global Top Spinal Muscular Atrophy Treatment Players by Revenue (2019-2024)
3.1.2 Global Spinal Muscular Atrophy Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Spinal Muscular Atrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Spinal Muscular Atrophy Treatment Revenue
3.4 Global Spinal Muscular Atrophy Treatment Market Concentration Ratio
3.4.1 Global Spinal Muscular Atrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy Treatment Revenue in 2023
3.5 Spinal Muscular Atrophy Treatment Key Players Head office and Area Served
3.6 Key Players Spinal Muscular Atrophy Treatment Product Solution and Service
3.7 Date of Enter into Spinal Muscular Atrophy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Spinal Muscular Atrophy Treatment Breakdown Data by Type
4.1 Global Spinal Muscular Atrophy Treatment Historic Market Size by Type (2019-2024)
4.2 Global Spinal Muscular Atrophy Treatment Forecasted Market Size by Type (2025-2030)
5 Spinal Muscular Atrophy Treatment Breakdown Data by Application
5.1 Global Spinal Muscular Atrophy Treatment Historic Market Size by Application (2019-2024)
5.2 Global Spinal Muscular Atrophy Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Spinal Muscular Atrophy Treatment Market Size (2019-2030)
6.2 North America Spinal Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024)
6.4 North America Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Spinal Muscular Atrophy Treatment Market Size (2019-2030)
7.2 Europe Spinal Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024)
7.4 Europe Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Spinal Muscular Atrophy Treatment Market Size (2019-2030)
8.2 Asia-Pacific Spinal Muscular Atrophy Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Spinal Muscular Atrophy Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Spinal Muscular Atrophy Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Spinal Muscular Atrophy Treatment Market Size (2019-2030)
9.2 Latin America Spinal Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024)
9.4 Latin America Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Spinal Muscular Atrophy Treatment Market Size (2019-2030)
10.2 Middle East & Africa Spinal Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Spinal Muscular Atrophy Treatment Introduction
11.1.4 Novartis AG Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.1.5 Novartis AG Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Spinal Muscular Atrophy Treatment Introduction
11.2.4 Pfizer Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Biogen
11.3.1 Biogen Company Detail
11.3.2 Biogen Business Overview
11.3.3 Biogen Spinal Muscular Atrophy Treatment Introduction
11.3.4 Biogen Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.3.5 Biogen Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Spinal Muscular Atrophy Treatment Introduction
11.4.4 Roche Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.4.5 Roche Recent Development
11.5 Cytokinetics
11.5.1 Cytokinetics Company Detail
11.5.2 Cytokinetics Business Overview
11.5.3 Cytokinetics Spinal Muscular Atrophy Treatment Introduction
11.5.4 Cytokinetics Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.5.5 Cytokinetics Recent Development
11.6 Ionis Pharmaceuticals
11.6.1 Ionis Pharmaceuticals Company Detail
11.6.2 Ionis Pharmaceuticals Business Overview
11.6.3 Ionis Pharmaceuticals Spinal Muscular Atrophy Treatment Introduction
11.6.4 Ionis Pharmaceuticals Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.6.5 Ionis Pharmaceuticals Recent Development
11.7 NMD Phrama
11.7.1 NMD Phrama Company Detail
11.7.2 NMD Phrama Business Overview
11.7.3 NMD Phrama Spinal Muscular Atrophy Treatment Introduction
11.7.4 NMD Phrama Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.7.5 NMD Phrama Recent Development
11.8 Beijing Jinlan Gene Technology
11.8.1 Beijing Jinlan Gene Technology Company Detail
11.8.2 Beijing Jinlan Gene Technology Business Overview
11.8.3 Beijing Jinlan Gene Technology Spinal Muscular Atrophy Treatment Introduction
11.8.4 Beijing Jinlan Gene Technology Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.8.5 Beijing Jinlan Gene Technology Recent Development
11.9 Hanugen Theraputics
11.9.1 Hanugen Theraputics Company Detail
11.9.2 Hanugen Theraputics Business Overview
11.9.3 Hanugen Theraputics Spinal Muscular Atrophy Treatment Introduction
11.9.4 Hanugen Theraputics Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.9.5 Hanugen Theraputics Recent Development
11.10 Scholar Rock Holding
11.10.1 Scholar Rock Holding Company Detail
11.10.2 Scholar Rock Holding Business Overview
11.10.3 Scholar Rock Holding Spinal Muscular Atrophy Treatment Introduction
11.10.4 Scholar Rock Holding Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024)
11.10.5 Scholar Rock Holding Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Spinal Muscular Atrophy Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Oral
Table 3. Key Players of Parenteral
Table 4. Global Spinal Muscular Atrophy Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Spinal Muscular Atrophy Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Spinal Muscular Atrophy Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Spinal Muscular Atrophy Treatment Market Share by Region (2019-2024)
Table 8. Global Spinal Muscular Atrophy Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Spinal Muscular Atrophy Treatment Market Share by Region (2025-2030)
Table 10. Spinal Muscular Atrophy Treatment Market Trends
Table 11. Spinal Muscular Atrophy Treatment Market Drivers
Table 12. Spinal Muscular Atrophy Treatment Market Challenges
Table 13. Spinal Muscular Atrophy Treatment Market Restraints
Table 14. Global Spinal Muscular Atrophy Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Spinal Muscular Atrophy Treatment Market Share by Players (2019-2024)
Table 16. Global Top Spinal Muscular Atrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Treatment as of 2023)
Table 17. Ranking of Global Top Spinal Muscular Atrophy Treatment Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Spinal Muscular Atrophy Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Spinal Muscular Atrophy Treatment Product Solution and Service
Table 21. Date of Enter into Spinal Muscular Atrophy Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Spinal Muscular Atrophy Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Spinal Muscular Atrophy Treatment Revenue Market Share by Type (2019-2024)
Table 25. Global Spinal Muscular Atrophy Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Spinal Muscular Atrophy Treatment Revenue Market Share by Type (2025-2030)
Table 27. Global Spinal Muscular Atrophy Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Spinal Muscular Atrophy Treatment Revenue Market Share by Application (2019-2024)
Table 29. Global Spinal Muscular Atrophy Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Spinal Muscular Atrophy Treatment Revenue Market Share by Application (2025-2030)
Table 31. North America Spinal Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Spinal Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Spinal Muscular Atrophy Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Spinal Muscular Atrophy Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Spinal Muscular Atrophy Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Spinal Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Spinal Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Spinal Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Spinal Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 46. Novartis AG Company Detail
Table 47. Novartis AG Business Overview
Table 48. Novartis AG Spinal Muscular Atrophy Treatment Product
Table 49. Novartis AG Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 50. Novartis AG Recent Development
Table 51. Pfizer Company Detail
Table 52. Pfizer Business Overview
Table 53. Pfizer Spinal Muscular Atrophy Treatment Product
Table 54. Pfizer Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. Biogen Company Detail
Table 57. Biogen Business Overview
Table 58. Biogen Spinal Muscular Atrophy Treatment Product
Table 59. Biogen Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 60. Biogen Recent Development
Table 61. Roche Company Detail
Table 62. Roche Business Overview
Table 63. Roche Spinal Muscular Atrophy Treatment Product
Table 64. Roche Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Cytokinetics Company Detail
Table 67. Cytokinetics Business Overview
Table 68. Cytokinetics Spinal Muscular Atrophy Treatment Product
Table 69. Cytokinetics Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 70. Cytokinetics Recent Development
Table 71. Ionis Pharmaceuticals Company Detail
Table 72. Ionis Pharmaceuticals Business Overview
Table 73. Ionis Pharmaceuticals Spinal Muscular Atrophy Treatment Product
Table 74. Ionis Pharmaceuticals Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 75. Ionis Pharmaceuticals Recent Development
Table 76. NMD Phrama Company Detail
Table 77. NMD Phrama Business Overview
Table 78. NMD Phrama Spinal Muscular Atrophy Treatment Product
Table 79. NMD Phrama Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 80. NMD Phrama Recent Development
Table 81. Beijing Jinlan Gene Technology Company Detail
Table 82. Beijing Jinlan Gene Technology Business Overview
Table 83. Beijing Jinlan Gene Technology Spinal Muscular Atrophy Treatment Product
Table 84. Beijing Jinlan Gene Technology Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 85. Beijing Jinlan Gene Technology Recent Development
Table 86. Hanugen Theraputics Company Detail
Table 87. Hanugen Theraputics Business Overview
Table 88. Hanugen Theraputics Spinal Muscular Atrophy Treatment Product
Table 89. Hanugen Theraputics Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 90. Hanugen Theraputics Recent Development
Table 91. Scholar Rock Holding Company Detail
Table 92. Scholar Rock Holding Business Overview
Table 93. Scholar Rock Holding Spinal Muscular Atrophy Treatment Product
Table 94. Scholar Rock Holding Revenue in Spinal Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 95. Scholar Rock Holding Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Spinal Muscular Atrophy Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Spinal Muscular Atrophy Treatment Market Share by Type: 2023 VS 2030
Figure 3. Oral Features
Figure 4. Parenteral Features
Figure 5. Global Spinal Muscular Atrophy Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Spinal Muscular Atrophy Treatment Market Share by Application: 2023 VS 2030
Figure 7. Early Stage Candidates Case Studies
Figure 8. Late Stage Candidates Case Studies
Figure 9. Spinal Muscular Atrophy Treatment Report Years Considered
Figure 10. Global Spinal Muscular Atrophy Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Spinal Muscular Atrophy Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Spinal Muscular Atrophy Treatment Market Share by Region: 2023 VS 2030
Figure 13. Global Spinal Muscular Atrophy Treatment Market Share by Players in 2023
Figure 14. Global Top Spinal Muscular Atrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Treatment as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy Treatment Revenue in 2023
Figure 16. North America Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Spinal Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 18. United States Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Spinal Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 22. Germany Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Spinal Muscular Atrophy Treatment Market Share by Region (2019-2030)
Figure 30. China Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Spinal Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 38. Mexico Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Spinal Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 42. Turkey Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Spinal Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Novartis AG Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 45. Pfizer Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 46. Biogen Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 47. Roche Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 48. Cytokinetics Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 49. Ionis Pharmaceuticals Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 50. NMD Phrama Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 51. Beijing Jinlan Gene Technology Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 52. Hanugen Theraputics Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 53. Scholar Rock Holding Revenue Growth Rate in Spinal Muscular Atrophy Treatment Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
